{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = verified
| Watchedfields = verified
| verifiedrevid = 443713428
| IUPAC_name = (6''R'',7''R'',8''R'',9''S'',10''R'',13''S'',14''S'',15''S'',16''S'',17''S'')-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimetylspiro-[17''H''-dicyclopropa[6,7:15,16]cyclopenta[''a'']phenantrene-17,2'(5<nowiki>'</nowiki>''H'')-furan]-3,5'(2''H'')-dione
| image = Drospirenone.svg
| width = 225px
| image2 = Drospirenone molecule ball.png
| width2 = 225px

<!--Clinical data-->
| pronounce = Droe-SPY-re-nown
| tradename = ''Alone'': Slynd<br />''With [[estradiol (medication)|estradiol]]'': Angeliq<br />''With [[ethinylestradiol]]'': Yasmin, Yasminelle, Yaz, others
| pregnancy_AU = 
| pregnancy_US = X
| legal_status = Rx-only
| routes_of_administration= [[Oral administration|By mouth]]<ref name="Kuhl2005">{{저널 인용|last1=Kuhl|first1=H|title=Pharmacology of estrogens and progestogens: influence of different routes of administration|journal=Climacteric|volume=8|issue=sup1|year=2005|pages=3–63|issn=1369-7137|doi=10.1080/13697130500148875|pmid=16112947|s2cid=24616324|url=}}</ref>
| class = [[Progestogen (medication)|Progestogen]]; [[Progestin]]; [[Antimineralocorticoid]]; [[Steroidal antiandrogen]]

<!--Pharmacokinetic data-->
| bioavailability= 66–85%<ref name="Kuhl2005" /><ref name="Krattenmacher2000">{{저널 인용|last1=Krattenmacher|first1=Rolf|title=Drospirenone: pharmacology and pharmacokinetics of a unique progestogen|journal=Contraception|volume=62|issue=1|year=2000|pages=29–38|issn=0010-7824|doi=10.1016/S0010-7824(00)00133-5|pmid=11024226}}</ref><ref name="pmid23238854">{{저널 인용| vauthors = Stanczyk FZ, Hapgood JP, Winer S, Mishell DR | title = Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects | journal = Endocr. Rev. | volume = 34 | issue = 2 | pages = 171–208 | date = April 2013 | pmid = 23238854 | pmc = 3610676 | doi = 10.1210/er.2012-1008 | url = }}</ref>
| protein_bound = 95–97% (to [[human serum albumin|albumin]])<ref name="Slynd-Label">{{웹 인용|title=Drospirenone tablets, for oral use |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf |website=FDA |accessdate=12 November 2019}}</ref><ref name="Kuhl2005" /><ref name="Krattenmacher2000" />
| metabolism = [[Liver]] (mostly [[cytochrome P450|CYP450]]-independent ([[redox|reduction]], [[sulfation]], and [[bond cleavage|cleavage]] of [[lactone]] [[ring (chemistry)|ring]]), some [[CYP3A4]] contribution)<ref name="Krattenmacher2000" /><ref name="Bachmann2009">{{저널 인용|last1=Bachmann|first1=Gloria|title=Drospirenone/ethinyl estradiol 3 mg/20 µg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin|journal=Patient Preference and Adherence|volume=3|year=2009|pages=259–64|issn=1177-889X|doi=10.2147/PPA.S3901|pmid=19936169|pmc=2778416}}</ref><ref name="WiesingerBerse2015">{{저널 인용|last1=Wiesinger|first1=Herbert|last2=Berse|first2=Matthias|last3=Klein|first3=Stefan|last4=Gschwend|first4=Simone|last5=Höchel|first5=Joachim|last6=Zollmann|first6=Frank S.|last7=Schütt|first7=Barbara|title=Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol|journal=British Journal of Clinical Pharmacology|volume=80|issue=6|year=2015|pages=1399–1410|issn=0306-5251|doi=10.1111/bcp.12745|pmid=26271371|pmc=4693482}}</ref>
| metabolites = • Drospirenone acid<ref name="Slynd-Label" /><br />• 4,5-Dihydrodrospirenone 3-sulfate<ref name="Slynd-Label" />
| elimination_half-life= 25–33 hours<ref name="Slynd-Label" /><ref name="Krattenmacher2000" /><ref name="Kuhl2005" />
| excretion = [[Urine]], [[feces]]<ref name="Slynd-Label" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 67392-87-4
| ATC_prefix = G03
| ATC_suffix = AC10
| ATC_supplemental = <br/>{{ATC|G03|AA12}} {{ATC|G03|FA17}} (combinations with [[estrogen (medication)|estrogens]])
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50838
| PubChem = 68873
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01395
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 62105
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N295J34A25
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1509
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03917
| synonyms = Dihydrospirenone; Dihydrospirorenone; 1,2-Dihydrospirorenone; MSp; SH-470; ZK-30595; LF-111; 17β-Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone

<!--Chemical data-->
| C=24 | H=30 | O=3
| SMILES = O=C7O[C@@]6([C@@]3([C@H]([C@@H]2[C@@H]4[C@H](/C1=C/C(=O)CC[C@]1(C)[C@H]2CC3)C4)[C@@H]5C[C@@H]56)C)CC7
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = METQSPRSQINEEU-HXCATZOESA-N
}}
'''드로스피레논'''(Drospirenone)은 사전경구피임약이다. 상품명으로는 [[바이엘 (기업)|바이엘]] 야스민과 [[바이엘 (기업)|바이엘]] 야즈가 있는데, 둘 다 한국에서 시판중이다.

== 4세대 피임약 ==
경구용 피임약은 2016년 현재 4세대가 시판중이다.
* 1세대: [[에티닐 에스트라디올]] 고용량(50Mg)
* 2세대: [[레보노게스트렐]](미니보라, 세스콘, 트리퀼라정, 에이리스정)
* 3세대: [[데소게스트렐]](머시론), [[게스토덴]](멜리안, 마이보라, 멜리안, 미뉴렛)
* 4세대: 드로스피레논(야스민정, 야즈정), [[디에노게스트]](클래라), [[노메게스트롤 아세테이트]](에리자정, 다이안느35정)

[[바이엘 (기업)|바이엘]]은 야스민 다음으로 2009년 야즈를 출시했는데, 28정에 25,000원 정도 가격이며, 2016년 현재 한국에서 평상시 복용하는 사전피임약 매출액 1위 의약품이다. 2위는 [[바이엘 (기업)|바이엘]] [[머시론]]이다.

== 부작용 ==

2012년 2월 춘천의 S병원에서 [[월경통]]을 겪던 환자가 야스민 3개월 처방을 받고 약 한달 후에 가슴이 답답하고 숨이 차는 증상 등을 보이다 사망했다. 2016년 5월 인천 검단지역 한 산부인과 의원에서 야스민을 처방받아 복용한 여성 환자가 사망했다.<ref>[단독]바이엘 사전피임약 '야스민' 복용후 사망자 또 발생, 뉴스1, 2016.07.13.</ref>

== 각주 ==
{{각주}}

{{전거 통제}}

[[분류:피임약]]
[[분류:프로게스토겐]]
[[분류:사이클로프로페인]]
[[분류:락톤]]
[[분류:항안드로겐]]
[[분류:엔온]]
[[분류:프레그난]]
[[분류:바이엘의 제품]]
[[분류:스테로이드성 항안드로겐]]